Daniel Janney - Sep 21, 2022 Form 4 Insider Report for Allakos Inc. (ALLK)

Role
Director, 10%+ Owner
Signature
/s/ Daniel Janney
Stock symbol
ALLK
Transactions as of
Sep 21, 2022
Transactions value $
$2,384,500
Form type
4
Date filed
9/23/2022, 04:25 PM
Previous filing
Jul 1, 2022
Next filing
Apr 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLK Common Stock Purchase $2.38M +475K +22.93% $5.02 2.55M Sep 21, 2022 By Alta Partners NextGen Fund I, L.P. F1, F2
holding ALLK Common Stock 6.45M Sep 21, 2022 By Alta Partners VIII, L.P. F3
holding ALLK Common Stock 56.3K Sep 21, 2022 By Alta Bioequities L.P. F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reports the purchase of shares in the underwritten public offering of common stock of the Issuer.
F2 The shares are directly held by Alta Partners NextGen Fund I, L.P. ("APNG I"). Alta Partners NextGen Fund I Management, LLC ("APNG I Management") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein.
F3 The shares are directly held by Alta Partners VIII, L.P. ("Alta VIII"). Alta Partners Management VIII, LLC ("Alta Management VIII") is the general partner of Alta VIII. The Reporting Person is a managing director of Alta Management VIII and, as such, may be deemed to share voting and investment control with respect to the shares held by Alta VIII. The Reporting Person disclaims beneficial ownership of all shares held by Alta VIII, except to the extent of his pecuniary interest therein.
F4 Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.